The Efficacy Of Transscleral Diode Laser Cyclophotocoagulation In Patients With Neovascular Glaucoma (Nvg) Compared To A Control Group Of Glaucoma Patients Without Nvg
Published 2026 - 44th Congress of the ESCRS
Reference: POGAU053 | Type: Free paper | DOI: 10.82333/jnb9-6z41
Authors: Dr Fadi Haddad* 1 , Mr Hillel Weisinger 2 , Mr Gad Cohen 2 , Dr Daniel Bahir 3
1Glaucoma,Mass Eye and Ear,Boston,United States;Ophthalmology,Tzafon Medical Center,Tiberias,Israel, 2Medical School,Bar-Ilan University,Safed,Israel, 3Ophthalmology,Tzafon Medical Center,Tiberias,Israel
Purpose
To assess the effect of cyclophotocoagulation diode laser in Neovascular Glaucoma versus non-Neovascular Glaucoma
Setting
A consecutive cohort of cases undergoing diode laser cyclophotocoagulation. Comparing the results of neovascular glaucoma to non-neovascular glaucoma.
Methods
A retrospective chart review of consecutive cases performed in the Tzafon Medical Center, Israel by a single surgeon. All cases were performed using continuous-wave laser using the Vitra cyclodiode device (Quantel, France) and were categorized as NVG or non-NVG eyes. The study received institutional review board approval.
The primary outcomes included: IOP and cumulative failure. Failure was defined as as IOP > 21 mmHg or reduced < 20% from baseline on 2 consecutive visits after 3 months, IOP ≤ 5 mmHg on 2 consecutive visits after 3 months, loss of light perception vision, reoperation for glaucoma. Secondary outcomes: glaucoma medications number, visual acuity, complications, and percentage of patients off oral acetazolamide.
Results
The study included 35 eyes in the NVG group, and 25 eyes in the non-NVG group. Pre-operative IOP was 38.1±10.1 and 34.6±9.3 mmHg and dropped to 20.5±13.2 and 16.8±6.4 mmHg at 1 year (p=0.16) in the NVG and non-NVG groups, respectively. The number of medications decreased from 5±1 in both groups pre-operatively to 3.5±0.5 and 3.5±1.0 at 1 year in the NVG and non-NVG groups (p=0.9).
At 1 year, failure occurred in 56.25% in NVG, and 45.5% in non-NVG (p=0.58).
Use of oral carbonic anhydrase inhibitors was 56.3% and 40.9% pre-operatively (p=0.27), and reduced to 9.4% and 18.2% (p=0.34) at 1-year in the NVG and non-NVG groups, respectively.
Conclusions
Despite not achieving statistically significant results due to low numbers, there was a trend towards higher IOP in the NVG group along with higher failure rate. there was no difference in the total number of medications, but a larger proportion of patients were without oral carbonic anhydrase inhibitors in the NVG group. The difference in oral acetazolamide treatment might explain the differences in IOP and failure rate. Larger studies are required to assess the effect of diode cyclophotocoagulation on NVG versus non-NVG eyes.